Drugs / Senza5 CART5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06420089 | Oct 2024 → Aug 2028 expected | T-cell non-Hodgkin lymphoma | Vittoria Biotherapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Senza5 CART5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420089 ↗ |
| Action | Inhibit | “CD5 knockout (KO)cells” NCT06420089 ↗ |
| Modality | Cell therapy | “engineered autologous T cells” NCT06420089 ↗ |
| Route | Intravenous | “Senza5 CART5 cells given as a single IV infusion” NCT06420089 ↗ |
| Target | CD5 | “CD5 knockout (KO)cells” NCT06420089 ↗ |